Evidence map›Paper›PMID 36059852›Full record

ArticleFrontiers in medicine2022

Increased histone citrullination in juvenile idiopathic arthritis.

Zuzana Parackova, Irena Zentsova, Hana Malcova, Dita Cebecauerova, Anna Sediva, Rudolf Horvath

Abstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zuzana ParackovaDepartment of Immunology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czechia.
Irena ZentsovaDepartment of Immunology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czechia.
Hana MalcovaDepartment of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia.
Dita CebecauerovaDepartment of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia.
Anna SedivaDepartment of Immunology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czechia.
Rudolf HorvathDepartment of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Posttranslational modifications (PTMs) of proteins are crucial for regulating various biological processes. However, protein alteration Methods: We recruited 30 pediatric patients with JIA (20 with active disease and 10 in remission) and 30 healthy donors. The serum concentrations of citrullinated histone H3 (citH3), peptidyl arginine deiminases (PADs), and NET-related products were detected using ELISA, and the number of citH3+ neutrophils was assessed using flow cytometry. Results: The serum levels of citH3 and PADs were higher in active as well as in remission JIA patients than in healthy donors. Similarly, the number of citH3+ neutrophils was higher in the peripheral blood of patients with JIA, implying an enhanced process of NETosis. This was effectively reflected by elevated serum levels of NET-associated products, such as neutrophil elastase, LL37, and cell-free DNA-histone complexes. Additionally, 16.7% of active JIA patients were seropositive for carbamylated autoantibodies, the levels of which declined sharply after initiation of anti-TNFα therapy. Conclusion: Collectively, our data suggest that the accelerated process of NETosis and PTMs in JIA may result in the generation of anti-citrullinated/carbamylated autoantibodies against various epitopes later in life, which could be prevented by effectively regulating inflammation using immune therapy.

Indexed as

carbamylationcitrullinationhistonejuvenile idiopathic arthritisNETosisneutrophilpeptidyl arginine deiminases (PAD)

Identifiers

PMID36059852
PMCPMC9437311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.